Technology is changing the future of healthcare. Genomics and e-healthcare are shaking up antiquated health systems. VanEck’s Genomics ETF invests in the innovative companies harnessing scientific advances to develop breakthrough treatments and give patients more control over how they access care.
Through tracking the companies driving healthcare’s future, our Genomics ETF aims to generate returns for investors. Such is the nature of healthcare’s modernization that it also brings clear social benefits through improved medical care and wider access to treatments.
Gene therapies focus on modifying cells to treat serious diseases. They target the fundamental causes of disease, potentially enabling cures for rare and inherited diseases. They may also have applications for more common conditions. New clinical data is expanding genetic therapy pipelines.
E-healthcare is a broad term used to describe how digital technologies are being deployed to improve efficiencies across the healthcare sector. The Covid-19 pandemic accelerated e-healthcare’s development – especially as patients were allowed to speak to doctors by video links rather than visiting hospitals and running the risk of contagion. Growing support from governments and hospitals, as well as advances in technology, is accelerating e-healthcare’s growth.
This risk exists when a particular financial instrument is difficult to purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price, or at all. This is a factor to consider before investing in a Genomics ETF.
The prices of the securities in the Fund are subject to the risks associated with investing in the securities market, including general economic conditions and sudden and unpredictable drops in value. An investment in the Fund may lose money.
The Fund’s assets may be concentrated in one or more particular sectors or industries. Genomics ETF may be subject to the risk that economic, political or other conditions that have a negative effect on the relevant sectors or industries will negatively impact the Fund's performance to a greater extent than if the Fund’s assets were invested in a wider variety of sectors or industries.
For more information on risks, please see the “Risk Factors” section of the relevant Fund’s prospectus, available on www.vaneck.com.